Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1
Key Points
Key points are not available for this paper at this time.
Abstract
NCT01695239; EudraCT2011-002326-49; Results.
AI से पूछें
Like
Bookmark
Share
View Full Paper
AI से पूछें
Like
Bookmark
Share
View Full Paper
Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1 | Synapse